- Quidel Corporation QDEL reported after the close of the market Thursday that its second-quarter revenues fell 12% Y/Y to $176.6 million, below the consensus of $194.5 million.
- The decline is attributable to decreased demand for Sofia and PCR COVID-19 assays and lower demand for influenza products.
- Excluding COVID-19 and influenza products, revenue for the core business grew 24% to $91.5 million.
- Sales of rapid immunoassay products decreased 25% to $60.1 million due to lower revenue for Sofia SARS Antigen and influenza products partially offset by $28.6 million in incremental QuickVue SARS Antigen product sales.
- Cardiometabolic immunoassay revenue totaled $71.7 million, up 32%. Quidel's specialized diagnostic solutions revenue decreased 12% to $10.4 million.
- Molecular diagnostic product sales fell 38% to $34.5 million, which Quidel attributed to a $25.5 million decline in sales of Lyra PCR assays for COVID-19 diagnosis partially offset by incremental revenue from its Solana SARS-CoV-2 assay.
- Total sales of COVID-19 products were $83.4 million compared to $109.0 million a year ago, while the firm's total sales of Influenza products were $1.6 million compared to $18.7 million a year ago.
- In Q2, Quidel settled a legal dispute with Beckman Coulter over its BNP cardiometabolic immunoassay business. Beckman assumed ownership of the business and provided Quidel with yearly cash payments of between $70 million - $75 million through 2029.
- The gross margin declined from 73.7% to 60.1%, driven by lower selling prices for SARS products and unfavorable product mix.
- Quidel's Q2 adjusted EPS of $0.75, down from $1.86 a year ago, missed the consensus of $1.46.
- It finished the quarter with $593.2 million in cash and cash equivalents.
- Price Action: QDEL shares traded lower by 7.64% at $133 premarket on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
